iSpecimen (ISPC) Common Equity (2020 - 2026)

iSpecimen's Common Equity history runs 7 years deep, the most recent figure standing at $814038.0 for Q1 2026.

• In Q1 2026, Common Equity fell 51.21% year-over-year to $814038.0; the TTM figure through Mar 2026 stood at $814038.0 (down 51.21% YoY), while the FY2025 annual figure was $3.1 million, down 6.73% from the prior year.
• Common Equity was $814038.0 for Q1 2026 at iSpecimen, down from $3.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $27.7 million in Q1 2022 to a low of $621973.0 in Q2 2025.
• Historically, Common Equity has averaged $10.7 million across 5 years, with a median of $6.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity soared 188.62% in 2022, then tumbled 89.79% in 2025.
• A 5-year view of Common Equity shows it stood at $20.3 million in 2022, then slumped by 52.04% to $9.7 million in 2023, then slumped by 66.01% to $3.3 million in 2024, then slipped by 6.73% to $3.1 million in 2025, then tumbled by 73.64% to $814038.0 in 2026.
• The last three Common Equity figures came in at $814038.0 (Q1 2026), $3.1 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.